News

Some trial results change the standard of care, while others affirm it. Both are valuable.

DART shows success in another rare cancer, and DART II is in the works

That's your PRO Core. Here's a five-year success update.

A new mentoring program is designed to engage APPs with SWOG and the NCTN

Fall group meeting registration opens Tuesday, August 13th

We've just selected five researchers to participate in this year's installment of our Early-Stage Investigator Training Course

Tumors with alterations in any of three specific DNA damage-repair genes were more likely than other tumors to be eliminated by cisplatin-based chemotherapy.